TYK2 and autoimmune disease: These first-generation inhibitors simultaneously bind to JAK1, JAK2, JAK3, TYK2, and other homologous targets, thereby blocking multiple downstream signaling pathways, thereby treating a variety of autoimmune diseases (41–43).